Literature DB >> 14550458

Transitional cell carcinoma in a fused crossed ectopic kidney.

Uri Gur1, Ofer Yossepowitch, Jack Baniel.   

Abstract

Nephroureterectomy is considered the reference standard treatment for invasive transitional cell carcinoma of the ureter. When this malignancy occurs in a patient with renal fusion anomaly, separating the involved kidney from its conjoint mate becomes a challenging task for the surgeon. We report a unique case in which a patient with an L-shaped left-to-right crossed ectopic kidney was diagnosed with invasive ureteral transitional cell carcinoma. The preoperative assessment in these uncommon cases should include renal angiography or computed tomography angiography to provide key information about the renal vasculature, which is essential for planning the surgical dissection and line of separation between the kidneys.

Entities:  

Mesh:

Year:  2003        PMID: 14550458     DOI: 10.1016/s0090-4295(03)00577-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Double trouble: pelvi-ureteric junction obstruction and renal cell carcinoma in right to left crossed fused ectopia.

Authors:  Sumit Saini; Siddharth Yadav; Brusabhanu Nayak
Journal:  BMJ Case Rep       Date:  2016-12-01

2.  Laparoscopic nephrolithotomy in a patient with crossed fused renal ectopia.

Authors:  Alireza Aminsharifi; Reza Niroomand; Mohsen Kroup; Mohammad Mehdi Hosseini
Journal:  Nat Rev Urol       Date:  2009-12       Impact factor: 14.432

3.  Robot-assisted heminephrectomy for chromophobe renal cell carcinoma in L-shaped fused crossed ectopia: Surgical challenge.

Authors:  Santosh Kumar; Shivanshu Singh; Siddharth Jain; Girdhar Singh Bora; Shrawan Kumar Singh
Journal:  Korean J Urol       Date:  2015-10-02

4.  Crossed-fused renal ectopia with renal calculi: Two case reports and a review of the literature.

Authors:  Yalei Cao; Yinan Zhang; Weiting Kang; Ning Suo; Zilian Cui; Yuanman Luo; Xunbo Jin
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.